德琪医药-B今日盘中大涨5.23%，引起了市场的广泛关注。
消息面上，公司近期公布了2025年年度业绩，显示营收同比增长14.56%至1.05亿元，经调整后年内亏损同比收窄33.7%至2.02亿元，同时公司现金储备充足，核心临床管线取得积极进展，管理层预计今年会陆续达成更多合作。
此外，公司创始人、首席执行官兼董事长梅建明博士，执行董事兼首席财务官龙振国先生，以及企业副总裁兼董事会秘书曹洋先生于近期在公开市场合计增持了公司股份，总代价约为385.3万港元。此举被市场解读为管理层对公司长期投资价值及未来发展前景抱有坚定信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.